container

Account Information

bundle-connector

footer-legal-menu

Terms of use

Privacy

secondary-account-menu

Profile

Orders

Wish List

Fast Order Entry

My Account

config

header-component

footer-legal-menu-component

secondary-storefront-menu

Would you like to go to the Gale {{RECOMMENDED_COUNTRY}} site instead?

It looks like you're visiting from {{DETECTED_COUNTRY}}.

main

products

Marketing materials, training documents, discovery services

cengage:card

FIND YOUR SALES REPRESENTATIVE

cengage:column

Get marketing materials, training documents, discovery services.

PRODUCT SUPPORT

CUSTOMER SUPPORT

Report technical issues, errors, check system status

TECHNICAL SUPPORT

Manage product preferences, generate usage reports, simplify administrative tasks.

ADMIN TOOLS

support

cengage:galethorndikeseo

International

North America

China

Japan

Latin America

Brazil

Region

Set your region:

zone1

secondary-primary-menu

mega-menu

footer-social-menu

Sign Up for Emails

CONNECT WITH GALE

Stay up-to-date with the latest Gale news, exclusive offers, and more.

facebook

linkedin

instagram

youtube

SOCIAL ICONS

About Us

Blogs

Press Center

Events

News

Careers

Our Company

Request a Trial

single-column

gale-footer

zone3

header

FIND YOUR REP

support-order-2

Browse by Institution Type

Browse by Product Type

Products

Support

%1 products have been added to your cart but %2 have been backordered and will be fulfilled when stock is available

Product on backorder

Current quantity limit is [maxProductQuantity], please, navigate to the cart page and change quantity of product

You will be able to resubmit promo in ${countdown} seconds. test

Please note that the taxes displayed on our website are estimated and subject to adjustment. The actual tax charges will be determined and settled during the final invoicing of your order

product-detail-component

footer-menu

Academic Institutions

K-12

Public Libraries

Government and Special Libraries

Statewide Programs

Institutions

Databases

Primary Sources

Digital Humanities Tools

eLearning

Schools/K-12 Curriculum

Books

Large Print Books by Thorndike Press

Find Your Rep

Product Support

Technical Support

Customer Support

Admin Tools

Accessibility Policy

Partnerships

Contact Us

footer-menu-component

zone2

footer

You may already have access to Gale content through your institution.

STUDENTS AND RESEARCHERS

support-order-1

footer-social-menu-component

The Path from Biomarker Discovery to Regulatory Qualification

PATH FROM BIOMARKER DISCVRY TO REGULATORY QUALIFICATION

Drugs & Pharmacology

Health, Medicine & Nursing

Gt Product Group

Binding Format

Marketing Imprint Name

B2B GT

CL Carton Count

Imprint Name

B2B & B2C

The Path from Biomarker Discovery to Regulatory Qualification is a unique guide that focuses on biomarker qualification, its history and current regulatory settings in both the US and abroad. This multi-contributed book provides a detailed look at the next step to developing biomarkers for clinical use and covers overall concepts, challenges, strategies and solutions based on the experiences of regulatory authorities and scientists. Members of the regulatory, pharmaceutical and biomarker development communities will benefit the most from using this book—it is a complete and practical guide to biomarker qualification, providing valuable insight to an ever-evolving and important area of regulatory science.

POST SECONDARY FOUR YEAR

COLFR

COLSO

COLJR

COLSR

Duration

Duration Unit Of Measure

Transaction Type

Front Cover.
Half Title Page.
Title Page.
Copyright Page.
Contents.
Contributors.
Preface.
1: Introduction.
2: Biomarker Applications in the Pharmaceutical Industry.
3: Impact of Biomarker Qualification Regulatory Processes on the Critical Path for Drug Development.
4: Regulatory Experience of Biomarker Qualification in the EMA.
5: Regulatory Experience at the FDA, EMA, and PMDA: Regulatory Experience at the PMDA.
6: Biomarker Development and Qualification in the Pharmaceutical Industry.
7: The Impact of Changing Context of Use on Weight of Evidence for Qualification of Biomarkers: A Case Study in Ischemic Stroke.
8: Safety Biomarker Development and Qualification in the Pharmaceutical Industry.
9: First-Ever Regulatory Biomarker Qualification &#x2013; Review and Insights by a Participant.
10: Metabolomics-Derived Biomarkers of Drug-Induced Skeletal Muscle Injury and Urinary Bladder Transitional Cell Carcinoma in Rats.
11: Molecular Biomarkers for Patients with Castration-Resistant Prostate Cancer: Validating Assays Predictive of Tumor Response.
12: Toxicogenomic Biomarkers.
13: Gene Logic and Toxicogenomics Biomarkers.
14: The When, Where and How of Toxicogenomic Submissions to Regulatory Agencies: The Deliberations of the HL7/CDISC/I3C Pharmacogenomics Data Standards Track 1 Toxicogenomics Working Group.
15: Biomarker Qualification &#x2013; Past, Present and Future: Initiating a Cross-Sector Toxicogenomics Biomarker Initiative &#x2013; Health and Environmental Sciences Institute (HESI) Committee on Application of Genomics to Mechanism-Based Risk Assessment.
16: Biomarkers of Drug Safety.
17: &#x2018;Classic&#x2019; Biomarkers of Liver Injury.
18: Qualification of Urinary Biomarkers for Kidney Toxicity.
19: Consortia.
20: Renal Biomarker Qualification: An ILSI Health and Environmental Sciences Institute Perspective.
21: Vignette Regarding Consortia: C-Path Institute.
22: The Telemetric and Holter ECG Warehouse to Enable the Validation and Development of Novel Electrocardiographic Markers.
23: Path to Regulatory Qualification Process Development.
24: Path to Regulatory Qualification Program Development: A US FDA Perspective.
25: Path to Regulatory Qualification Process Development.
26: The Tortuous Path From Development to Qualification of Biomarkers.
Index.

The Path from Biomarker Discovery to Regulatory Qualification.css-1p8rvzy{position:absolute;padding-left:8px;}

The Path from Biomarker Discovery to Regulatory Qualification